Clinical Trial Update: Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating isotretinoin, interferon alfa-2b, docetaxel, and estramustine in metastatic prostate cancer unresponsive to hormone therapy; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Estracyt (estramustine phosphate)
• ISOTRETINOIN (Isotretinoin)
• Interferon alfa-2b (interferon alfa-2b)
• Taxotere (docetaxel)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED